EVIDENCE MAP OF COST-BENEFIT, COST-EFFECTIVENESS AND COST-UTILITY MODELS IN DEMENTIA PUBLISHED SINCE 1960
Author(s)
Martin A
Crystallise Ltd., East Tilbury, UK
Presentation Documents
METHODS: We searched the heoro.com database (www.heoro.com) for cost-benefit, cost-effectiveness or cost-utility modelling studies in dementia that were published between 1960 and th May 2017dementia
RESULTS: We found a total of abstracts. Of these, and this was unclear in 49Most reported models for Alzheimer’s disease (66 abstracts) or any type of dementia (59). Drug therapies were the most common interventions, in particular donepezil (26), memantine (25), rivastigmine (13), galantamine (12) or any anticholinesterase (15), but screening or diagnostic approaches (16) and caregiver support interventions (14) were also frequently modelled. The jurisdiction of 42 models was the United Kingdom, the United States, and 26 were reviews of the international modelling literature abstracts, were published between 2010 and 201 and were published beforeCONCLUSIONS: The focus on cost-utility models from a societal perspective reflects the high impact of dementia on quality of life of patients and caregivers. This is also shown by the substantial number of models on caregiver support and patient care interventions, as well as drug therapies. The preponderance of studies from the UK may reflect the burden on state-funded social care organisations in this country.
Conference/Value in Health Info
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PND42
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders